Generic Kyprolis Availability
Last updated on Oct 9, 2024.
Kyprolis is a brand name of carfilzomib, approved by the FDA in the following formulation(s):
KYPROLIS (carfilzomib - powder;intravenous)
-
Manufacturer: ONYX PHARMS AMGEN
Approval date: July 20, 2012
Strength(s): 60MG/VIAL [RLD] [AP] -
Manufacturer: ONYX PHARMS AMGEN
Approval date: June 3, 2016
Strength(s): 30MG/VIAL [RLD] -
Manufacturer: ONYX PHARMS AMGEN
Approval date: June 7, 2018
Strength(s): 10MG/VIAL [RLD]
Has a generic version of Kyprolis been approved?
A generic version of Kyprolis has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Kyprolis and have been approved by the FDA:
carfilzomib powder;intravenous
-
Manufacturer: DR REDDYS
Approval date: September 9, 2019
Strength(s): 60MG/VIAL [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Kyprolis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,232,818
Patent expiration dates:
- April 14, 2025✓✓
- April 14, 2025
-
Patent 7,417,042
Patent expiration dates:
- July 20, 2026✓✓
- July 20, 2026
-
Patent 7,491,704
Patent expiration dates:
- April 14, 2025✓
- April 14, 2025✓
- April 14, 2025✓
- April 14, 2025✓
- April 14, 2025
-
Patent 7,737,112
Patent expiration dates:
- December 7, 2027✓
- December 7, 2027
-
Compounds for enzyme inhibition
Patent 8,129,346
Issued: March 6, 2012
Inventor(s): Smyth Mark S. & Laidig Guy J. & Borchardt Ronald T. & Bunin Barry A. & Crews Craig M. & Musser John H.
Assignee(s): Onyx Therapeutics, Inc.Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Patent expiration dates:
- April 14, 2025✓
- April 14, 2025✓
- April 14, 2025✓
- April 14, 2025✓
- April 14, 2025
-
Compounds for enzyme inhibition
Patent 8,207,125
Issued: June 26, 2012
Inventor(s): Smyth Mark S. & Laidig Guy J.
Assignee(s): Onyx Therapeutics, Inc.Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Patent expiration dates:
- April 14, 2025✓✓
- April 14, 2025
-
Compounds for enzyme inhibition
Patent 8,207,126
Issued: June 26, 2012
Inventor(s): Smyth Mark S. & Laidig Guy J.
Assignee(s): Onyx Therapeutics, Inc.Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Patent expiration dates:
- April 14, 2025✓
- April 14, 2025
-
Compounds for enzyme inhibition
Patent 8,207,127
Issued: June 26, 2012
Inventor(s): Smyth Mark S. & Laidig Guy J.
Assignee(s): Onyx Technologies, Inc.Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Patent expiration dates:
- April 14, 2025✓
- April 14, 2025✓
- April 14, 2025✓
- April 14, 2025✓
- April 14, 2025
-
Compounds for enzyme inhibition
Patent 8,207,297
Issued: June 26, 2012
Inventor(s): Smyth Mark S. & Laidig Guy J.
Assignee(s): Onyx Therapeutics, Inc.Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Patent expiration dates:
- April 14, 2025✓✓
- April 14, 2025
-
Alkylated cyclodextrin compositions and processes for preparing and using the same
Patent 9,493,582
Issued: November 15, 2016
Inventor(s): Antle Vincent D. & Lopes Alvaro & Monteiro Daniel
Assignee(s): Cydex Pharmaceuticals, Inc.The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride.
Patent expiration dates:
- February 27, 2033✓
- February 27, 2033
-
Combination therapy with peptide epoxyketones
Patent RE47954
Issued: April 21, 2020
Inventor(s): Kirk Christopher J. & Demo Susan D. & Bennett Mark K.
Assignee(s): Onyx Therapeutics, Inc.ABSTRACT The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
Patent expiration dates:
- October 21, 2029✓
- October 21, 2029
More about Kyprolis (carfilzomib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: proteasome inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
AP | Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.